Augmentation Strategies for Clozapine-Resistant Patients with Schizophrenia

Author(s): Yi-Hang Chiu, Chia-Yueh Hsu, Mong-Liang Lu, Chun-Hsin Chen*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 2 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Clozapine has been used in treatment-resistant patients with schizophrenia. However, only 40% of patients with treatment-resistant schizophrenia have response to clozapine. Many augmentation strategies have been proposed to treat those clozapine-resistant patients, but the results are inconclusive. In this review, we intended to review papers dealing with the augmentation strategies in the treatment of clozapineresistant patients with schizophrenia.

Method: We reviewed randomized, double-blind, placebo- or sham-controlled trials (RCT) for clozapine-resistant patients with schizophrenia in Embase, PsycINFO, Cochrane, and PubMed database from January 1990 to June 2019.

Results: Antipsychotics, antidepressants, mood stabilizers, brain stimulation, such as electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation, and other strategies, were used as an augmentation in clozapine-resistant patients with schizophrenia. Except for better evidence in memantine with 2 RCTs and cognitive behavior therapy in 2 studies to support its effectiveness, we found that all the other effective augmentations, including sulpiride, ziprasidone, duloxetine, mirtazapine, ECT, sodium benzoate, ginkgo biloba, and minocycline, had only one RCT with limited sample size.

Conclusion: In this review, no definite effective augmentation strategy was found for clozapine-resistant patients. Some potential strategies with beneficial effects on psychopathology need further studies with a larger sample size to support their efficacy.

Keywords: Augmentation, clozapine-resistant, antipsychotics, antidepressants, mood stabilizers, psychopathology, schizophrenia.

[1]
Hasan A, Falkai P, Wobrock T, et al. World federation of societies of biological psychiatry (WFSBP) task force on treatment guidelines for schizophrenia. world federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13(5): 318-78.
[http://dx.doi.org/10.3109/15622975.2012.696143] [PMID: 22834451]
[2]
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789-96.
[http://dx.doi.org/10.1001/archpsyc.1988.01800330013001] [PMID: 3046553]
[3]
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394(10202): 939-51.
[http://dx.doi.org/10.1016/S0140-6736(19)31135-3] [PMID: 31303314]
[4]
Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 2017; 62(11): 772-7.
[http://dx.doi.org/10.1177/0706743717718167] [PMID: 28655284]
[5]
Siskind DJ, Lee M, Ravindran A, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry 2018; 52(8): 751-67.
[http://dx.doi.org/10.1177/0004867418772351] [PMID: 29732913]
[6]
Tang YL, Mao PX, Jiang F, et al. Clozapine in China. Pharmacopsychiatry 2008; 41(1): 1-9.
[http://dx.doi.org/10.1055/s-2007-993224] [PMID: 18203045]
[7]
Wang C, Li L. Proper use of clozapine: experiences in China. Shanghai Jingshen Yixue 2012; 24(2): 108-9.
[PMID: 25324611]
[8]
Overall JE, Pfefferbaum B. The brief psychiatric rating scale for children. Psychopharmacol Bull 1982; 18(2): 10-6.
[PMID: 7111598]
[9]
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261-76.
[http://dx.doi.org/10.1093/schbul/13.2.261] [PMID: 3616518]
[10]
Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. British J Psychol 1989; 155(S7): 49-52.
[11]
Andreasen NC. Scale for the assessment of positive symptoms (SAPS). Iowa: University of Iowa 1984.
[12]
Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280(1): 83-97.
[PMID: 8996185]
[13]
Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008; 41(1): 24-8.
[http://dx.doi.org/10.1055/s-2007-993209] [PMID: 18203048]
[14]
Barnes TRE, Leeson V, Paton C, et al. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol 2018; 8(7): 185-97.
[http://dx.doi.org/10.1177/2045125318762365] [PMID: 29977519]
[15]
Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28(8): 1400-11.
[http://dx.doi.org/10.1038/sj.npp.1300203] [PMID: 12784105]
[16]
Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69(5): 720-31.
[http://dx.doi.org/10.4088/JCP.v69n0505] [PMID: 18370574]
[17]
Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011; 127(1-3): 93-9.
[http://dx.doi.org/10.1016/j.schres.2010.12.011] [PMID: 21262565]
[18]
Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13(8): 1115-25.
[http://dx.doi.org/10.1017/S1461145710000490] [PMID: 20459883]
[19]
Friedman JI, Lindenmayer JP, Alcantara F, et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 2011; 36(6): 1289-95.
[http://dx.doi.org/10.1038/npp.2011.14] [PMID: 21346734]
[20]
Gunduz-Bruce H, Oliver S, Gueorguieva R, et al. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophr Res 2013; 143(2-3): 344-7.
[http://dx.doi.org/10.1016/j.schres.2012.11.008] [PMID: 23219861]
[21]
Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66(1): 63-72.
[http://dx.doi.org/10.4088/JCP.v66n0109] [PMID: 15669890]
[22]
Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92(1-3): 90-4.
[http://dx.doi.org/10.1016/j.schres.2006.12.030] [PMID: 17321111]
[23]
Honer WG, Thornton AE, Chen EY, et al. Clozapine and risperidone enhancement (CARE) study group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354(5): 472-82.
[http://dx.doi.org/10.1056/NEJMoa053222] [PMID: 16452559]
[24]
Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162(1): 130-6.
[http://dx.doi.org/10.1176/appi.ajp.162.1.130] [PMID: 15625211]
[25]
Weiner E, Conley RR, Ball MP, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010; 35(11): 2274-83.
[http://dx.doi.org/10.1038/npp.2010.101] [PMID: 20664583]
[26]
Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2012; 32(2): 173-8.
[http://dx.doi.org/10.1097/JCP.0b013e318248dfb8] [PMID: 22367659]
[27]
O’Connor SE, Brown RA. The pharmacology of sulpiride-a dopamine receptor antagonist. Gen Pharmacol 1982; 13(3): 185-93.
[http://dx.doi.org/10.1016/0306-3623(82)90088-X] [PMID: 7047291]
[28]
Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-73.
[http://dx.doi.org/10.1192/bjp.171.6.569] [PMID: 9519099]
[29]
Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002; 24(1): 21-37.
[http://dx.doi.org/10.1016/S0149-2918(02)85003-2] [PMID: 11833834]
[30]
Muscatello MR, Pandolfo G, Micò U, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34(1): 129-33.
[http://dx.doi.org/10.1097/JCP.0000000000000042] [PMID: 24145221]
[31]
Mico’ U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011; 26(6): 303-10.
[http://dx.doi.org/10.1097/YIC.0b013e32834bbc0d] [PMID: 21934625]
[32]
Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153(12): 1625-7.
[http://dx.doi.org/10.1176/ajp.153.12.1625] [PMID: 8942462]
[33]
Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004; 19(2): 71-6.
[http://dx.doi.org/10.1097/00004850-200403000-00003] [PMID: 15076014]
[34]
Tiihonen J, Hallikainen T, Ryynänen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54(11): 1241-8.
[http://dx.doi.org/10.1016/S0006-3223(03)00524-9] [PMID: 14643092]
[35]
Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007; 93(1-3): 109-16.
[http://dx.doi.org/10.1016/j.schres.2007.02.009] [PMID: 17383857]
[36]
Vayısoğlu S, Anıl Yağcıoğlu AE, Yağcıoğlu S, et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res 2013; 143(1): 207-14.
[http://dx.doi.org/10.1016/j.schres.2012.11.006] [PMID: 23217729]
[37]
Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol (Oxford) 2011; 25(5): 667-74.
[http://dx.doi.org/10.1177/0269881110372548] [PMID: 20615930]
[38]
Weiner RD. American psychiatric association The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (a task force report of the American psychiatric association). American Psychiatric Pub 2008.
[39]
Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 2015; 172(1): 52-8.
[http://dx.doi.org/10.1176/appi.ajp.2014.13060787] [PMID: 25157964]
[40]
Rosa MO, Gattaz WF, Rosa MA, et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. J Clin Psychiatry 2007; 68(10): 1528-32.
[http://dx.doi.org/10.4088/JCP.v68n1009] [PMID: 17960967]
[41]
de Jesus DR, Gil A, Barbosa L, et al. A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Res 2011; 188(2): 203-7.
[http://dx.doi.org/10.1016/j.psychres.2010.11.022] [PMID: 21186062]
[42]
Wagner E, Wobrock T, Kunze B, et al. Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. Schizophr Res 2019; 208: 370-6.
[http://dx.doi.org/10.1016/j.schres.2019.01.021] [PMID: 30704862]
[43]
Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987; 325(6104): 529-31.
[http://dx.doi.org/10.1038/325529a0] [PMID: 2433595]
[44]
Diaz P, Bhaskara S, Dursun SM, Deakin B. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25(3): 277-8.
[http://dx.doi.org/10.1097/01.jcp.0000165740.22377.6d] [PMID: 15876911]
[45]
Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157(5): 826-8.
[http://dx.doi.org/10.1176/appi.ajp.157.5.826] [PMID: 10784481]
[46]
Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156(1): 145-7.
[http://dx.doi.org/10.1176/ajp.156.1.145] [PMID: 9892314]
[47]
Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60(6): 645-9.
[http://dx.doi.org/10.1016/j.biopsych.2006.04.005] [PMID: 16780811]
[48]
Lin CH, Lin CH, Chang YC, et al. Sodium Benzoate, a D-Amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2018; 84(6): 422-32.
[http://dx.doi.org/10.1016/j.biopsych.2017.12.006] [PMID: 29397899]
[49]
de Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70(10): 1416-23.
[http://dx.doi.org/10.4088/JCP.08m04935gry] [PMID: 19906345]
[50]
Veerman SR, Schulte PF, Deijen JB, de Haan L. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med 2017; 47(2): 363-75.
[http://dx.doi.org/10.1017/S0033291716002476] [PMID: 27776560]
[51]
Stryjer R, Strous R, Bar F, et al. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Hum Psychopharmacol 2004; 19(5): 343-6.
[http://dx.doi.org/10.1002/hup.595] [PMID: 15252826]
[52]
Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15(4): 287-310.
[http://dx.doi.org/10.2165/00023210-200115040-00004] [PMID: 11463134]
[53]
Doruk A, Uzun O, Ozşahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2008; 23(4): 223-7.
[http://dx.doi.org/10.1097/YIC.0b013e3282fcff2f] [PMID: 18545061]
[54]
Valipour G, Saneei P, Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab 2014; 99(10): 3863-72.
[http://dx.doi.org/10.1210/jc.2014-1887] [PMID: 25050991]
[55]
Krivoy A, Onn R, Vilner Y, et al. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine 2017; 26: 138-45.
[http://dx.doi.org/10.1016/j.ebiom.2017.11.027] [PMID: 29226809]
[56]
Chaves C, Marque CR, Trzesniak C, et al. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res 2009; 42(11): 1002-14.
[http://dx.doi.org/10.1590/S0100-879X2009001100002] [PMID: 19855900]
[57]
Chu LS, Fang SH, Zhou Y, et al. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin 2007; 28(6): 763-72.
[http://dx.doi.org/10.1111/j.1745-7254.2007.00578.x] [PMID: 17506934]
[58]
Kelly DL, Sullivan KM, McEvoy JP, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol 2015; 35(4): 374-81.
[http://dx.doi.org/10.1097/JCP.0000000000000345] [PMID: 26082974]
[59]
Barretto EM, Kayo M, Avrichir BS, et al. A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. J Nerv Ment Dis 2009; 197(11): 865-8.
[http://dx.doi.org/10.1097/NMD.0b013e3181be7422] [PMID: 19996727]
[60]
Morrison AP, Pyle M, Gumley A, et al. FOCUS trial group. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. Lancet Psychiatry 2018; 5(8): 633-43.
[http://dx.doi.org/10.1016/S2215-0366(18)30184-6] [PMID: 30001930]
[61]
Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20(5-6): 409-15.
[http://dx.doi.org/10.1016/j.eurpsy.2004.12.007] [PMID: 16171655]
[62]
Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand 2009; 119(438): 7-14.
[http://dx.doi.org/10.1111/j.1600-0447.2008.01308.x] [PMID: 19132961]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 2
Year: 2020
Page: [218 - 227]
Pages: 10
DOI: 10.2174/1381612826666200110102254
Price: $65

Article Metrics

PDF: 47
HTML: 8
EPUB: 1
PRC: 2